Stock comparison
GILEAD SCIENCES, INC. is 5.5x more valuable than Moderna, Inc. by market capitalization ($167.49 B vs $30.38 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
GILD is larger
GILEAD SCIENCES, INC. is 5.5x more valuable than Moderna, Inc. by market capitalization ($167.49 B vs $30.38 B).
Market value leader
GILD
GILEAD SCIENCES, INC. is 5.5x more valuable than Moderna, Inc. by market capitalization ($167.49 B vs $30.38 B).
Revenue leader
GILD
GILD: $29.44B vs MRNA: $1.94B.
Profit leader
GILD
GILD: $8.51B vs MRNA: -$2.82B.
Margin leader
GILD
GILD: 28.9% vs MRNA: -145.2% net margin.
| Metric | GILD | MRNA |
|---|---|---|
| Market cap | $167.49 B | $30.38 B |
| US-listed rank | #92 | #461 |
| Revenue (latest FY) | $29.44B | $1.94B |
| Net income (latest FY) | $8.51B | -$2.82B |
| Net margin | 28.9% | -145.2% |
| P/E (trailing FY) | 19.7x | - |
| SEC filings | 968 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
GILEAD SCIENCES, INC. is 5.5x more valuable than Moderna, Inc. by market capitalization ($167.49 B vs $30.38 B).
In their latest fiscal years, GILEAD SCIENCES, INC. reported $29.44B in revenue while Moderna, Inc. reported $1.94B.
Full pages: GILEAD SCIENCES, INC. and Moderna, Inc., or browse the full rankings.